CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH This study compared the efficacy and safety of four different treatment regimens for patients with chronic lymphocytic leukemia (CLL): chemoimmunotherapy, venetoclax-rituximab, venetoclax-obinutuzumab, and venetoclax-obinutuzumab-ibrutinib.
The results showed that the venetoclax-obinutuzumab-ibrutinib regimen was the most effective, with significantly higher rates of undetectable minimal residual disease (MRD) and progression-free survival (PFS) at 15 months and 3 years, respectively, compared to the other regimens. The venetoclax-obinutuzumab regimen was also effective, with significantly higher rates of undetectable MRD at 15 months compared to chemoimmunotherapy. However, there was no significant difference in PFS at 3 years between the venetoclax-obinutuzumab and chemoimmunotherapy regimens.
The venetoclax-rituximab regimen was the least effective, with no significant difference in undetectable MRD or PFS at 15 months or 3 years compared to chemoimmunotherapy.
The most common adverse events were infections, which were more common with chemoimmunotherapy and venetoclax-obinutuzumab-ibrutinib than with the other regimens.
